Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/53218
Type
ArticleCopyright
Open access
Collections
- IOC - Artigos de Periódicos [12488]
Metadata
Show full item record
LABORATORY BIOMARKERS FOR DIAGNOSIS AND PROGNOSIS IN COVID-19
Author
Affilliation
Anesthesia and Intensive Care, San Martino Policlinico Hospital, Instituto di Ricovero e Cura a Carattere Scientifico (IRCCS) for Oncology and Neuroscience. Genoa, Italy / Department of Surgical Science and Integrated Diagnostics (DISC), University of Genoa. Genoa, Italy / Department of Medicine, University of Barcelona, Barcelona, Spain.
Universidade Federal do Rio de Janeiro. Instituto de Biofisica Carlos Chagas Filho. Laboratório de Investigação Pulmonar. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ, Brasil.
Anesthesia and Intensive Care, San Martino Policlinico Hospital, Instituto di Ricovero e Cura a Carattere Scientifico (IRCCS) for Oncology and Neuroscience. Genoa, Italy / Department of Surgical Science and Integrated Diagnostics (DISC), University of Genoa. Genoa, Italy.
Universidade Federal do Rio de Janeiro. Instituto de Biofisica Carlos Chagas Filho. Laboratório de Investigação Pulmonar. Rio de Janeiro, RJ, Brasil / COVID-19 Virus Network from Brazilian Council for Scientific and Technological Development. Brasília, Brasil / COVID-19 Virus Network from Brazilian Council for Scientific and Technological Development, Brasília, DF, Brasil.
Universidade Federal do Rio de Janeiro. Instituto de Biofisica Carlos Chagas Filho. Laboratório de Investigação Pulmonar. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ, Brasil.
Anesthesia and Intensive Care, San Martino Policlinico Hospital, Instituto di Ricovero e Cura a Carattere Scientifico (IRCCS) for Oncology and Neuroscience. Genoa, Italy / Department of Surgical Science and Integrated Diagnostics (DISC), University of Genoa. Genoa, Italy.
Universidade Federal do Rio de Janeiro. Instituto de Biofisica Carlos Chagas Filho. Laboratório de Investigação Pulmonar. Rio de Janeiro, RJ, Brasil / COVID-19 Virus Network from Brazilian Council for Scientific and Technological Development. Brasília, Brasil / COVID-19 Virus Network from Brazilian Council for Scientific and Technological Development, Brasília, DF, Brasil.
Abstract
Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) causes a wide spectrum
of clinical manifestations, with progression to multiorgan failure in the most severe cases.
Several biomarkers can be altered in coronavirus disease 2019 (COVID-19), and they can
be associated with diagnosis, prognosis, and outcomes. The most used biomarkers in
COVID-19 include several proinflammatory cytokines, neuron-specific enolase (NSE),
lactate dehydrogenase (LDH), aspartate transaminase (AST), neutrophil count,
neutrophils-to-lymphocytes ratio, troponins, creatine kinase (MB), myoglobin, D-dimer,
brain natriuretic peptide (BNP), and its N-terminal pro-hormone (NT-proBNP). Some of
these biomarkers can be readily used to predict disease severity, hospitalization, intensive
care unit (ICU) admission, and mortality, while others, such as metabolomic and
proteomic analysis, have not yet translated to clinical practice. This narrative review
aims to identify laboratory biomarkers that have shown significant diagnostic and
prognostic value for risk stratification in COVID-19 and discuss the possible clinical
application of novel analytic strategies, like metabolomics and proteomics. Future
research should focus on identifying a limited but essential number of laboratory
biomarkers to easily predict prognosis and outcome in severe COVID-19.
Share